Otsuka's 'Convoluted' Logic Spurned In Abilify Maintena Row
A D.C. federal judge on Thursday rejected Otsuka Pharmaceutical's effort to derail a rival version of schizophrenia drug Abilify Maintena, calling its logic "convoluted" and obviously aimed at perpetually thwarting competition....To view the full article, register now.
Already a subscriber? Click here to view full article